
    
      This eight-week study aims to assess the effectiveness and tolerability of escitalopram in
      improving symptoms of Major Depression in patients with Amyotrophic Lateral Sclerosis (ALS)
      or Multiple Sclerosis (MS) as measured by the HAM-D. In addition, the study will assess
      improvement in the quality of life in patients with Major Depression and ALS or MS.
    
  